Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

[Ac-225]-PSMA-62 Phase I/II Clinical Trial to Characterize Efficacy, Safety, Tolerability, and Dosimetry in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer (ACCEL)

NCT06229366 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT06229366
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06229366 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
[Ac-225]-PSMA-62 Phase I/II Clinical Trial to Characterize Efficacy, Safety, Tolerability, and Dosimetry in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer (ACCEL)
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 3, 2024
Completion date
December 31, 2032
Enrollment
142 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

hormone sensitive prostate cancer, metastatic castration-resistant prostate cancer, oligometastatic prostate carcinoma, prostate cancer